Application of pharmaceutical QbD for enhancement of the solubility and dissolution of a class II BCS drug using polymeric surfactants and crystallization inhibitors: Development of controlled-release tablets

AAPS PharmSciTech

Volumn 12, Issue 3, 2011, Pages 799-810

  Basalious, Emad B ^a   El Sebaie, Wessam ^a   El Gazayerly, Omaima ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Box Behnken design; dissolution; felodipine; QbD; solid mixture

Indexed keywords

CARBOPOL 974P; FELODIPINE; HYDROXYPROPYLMETHYLCELLULOSE; POLOXAMER; POLYMER; SURFACTANT;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; CRYSTALLIZATION; DISSOLUTION; DRUG SOLUBILITY; PRIORITY JOURNAL; TABLET MATRIX;

CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; FELODIPINE; KINETICS; METHYLCELLULOSE; POLOXAMER; POLYVINYLS; SOLUBILITY; SOLVENTS; TABLETS; TOTAL QUALITY MANAGEMENT;

EID: 80052568927     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/s12249-011-9646-6     Document Type: Article

References (31)

1. Nasr M. FDA's quality initiatives: an update. http://www.gmpcompliance. com/daten/download/FDAs-Quality-Initiative.pdf. Accessed 18 Nov 2010.
2. Food and Drug Administration CDER. Guidance for industry, Q8 (R2) pharmaceutical development (November 2009).
3. LX Yu 2008 Pharmaceutical quality by design: product and process development, understanding, and control Pharm Res 25 4 781 91 18185986 10.1007/s11095-007-9511-1 1:CAS:528:DC%2BD1cXkt1Sntrg%3D
4. KR Lee EJ Kim SW Seo HK Choi 2008 Effect of poloxamer on the dissolution of felodipine and preparation of controlled release matrix tablets containing felodipine Arch Pharm Res 31 8 1023 8 18787792 10.1007/s12272-001-1263-9 1:CAS:528:DC%2BD1cXhtVClurrJ
5. J Kerc S Srcic Z Knez P Sencar-Bozic 1999 Micronization of drugs using supercritical carbon dioxide Int J Pharm 182 1 33 9 10332072 10.1016/S0378-5173(99)00063-0 1:CAS:528:DyaK1MXjtVyksr0%3D (Pubitemid 29229792)
6. E Karavas G Ktistis A Xenakis E Georgarakis 2005 Miscibility behavior and formation mechanism of stabilized felodipine-polyvinylpyrrolidone amorphous solid dispersions Drug Dev Ind Pharm 31 6 473 89 16109621 10.1080/ 03639040500215958 1:CAS:528:DC%2BD2MXhtVCgu7zO (Pubitemid 41285726)
7. E Karavas E Georgarakis MP Sigalas K Avgoustakis D Bikiaris 2007 Investigation of the release mechanism of a sparingly water-soluble drug from solid dispersions in hydrophilic carriers based on physical state of drug, particle size distribution and drug-polymer interactions Eur J Pharm Biopharm 66 3 334 47 17267194 10.1016/j.ejpb.2006.11.020 1:CAS:528:DC%2BD2sXlsFKmtLg%3D (Pubitemid 46778978)
8. EJ Kim MK Chun JS Jang IH Lee KR Lee HK Choi 2006 Preparation of a solid dispersion of felodipine using a solvent wetting method Eur J Pharm Biopharm 64 2 200 5 16750355 10.1016/j.ejpb.2006.04.001 1:CAS:528:DC%2BD28Xptlyktb8%3D (Pubitemid 44291986)
9. M Vogt K Kunath JB Dressman 2008 Dissolution improvement of four poorly water soluble drugs by cogrinding with commonly used excipients Eur J Pharm Biopharm 68 330 7 17574401 10.1016/j.ejpb.2007.05.009 1:CAS:528: DC%2BD1cXlsF2rsQ%3D%3D
10. H Konno LS Taylor 2006 Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine J Pharm Sci 95 12 2692 705 16892209 10.1002/jps.20697 1:CAS:528:DC%2BD28XhtlSis7%2FE (Pubitemid 46093176)
11. H Konno LS Taylor 2007 Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture Pharm Res 25 4 969 78 17520180 10.1007/s11095-007-9331-3 (Pubitemid 351661822)
12. H Konno T Handa DE Alonzo LS Taylor 2008 Effect of polymer type on the dissolution profile of amorphous solid dispersions containing felodipine Eur J Pharm Biopharm 70 493 9 18577451 10.1016/j.ejpb.2008.05.023 1:CAS:528: DC%2BD1cXhtFOmtbnE
13. SK Motwani S Chopra S Talegaonkar K Kohli FJ Ahmad RK Khar 2008 Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation Eur J Pharm Biopharm 68 3 513 25 17983737 1:CAS:528:DC%2BD1cXjtVeksLk%3D (Pubitemid 351318222)
14. DH Won MS Kim S Lee JS Park SJ Hwang 2005 Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process Int J Pharm 301 1-2 199 208 16024189 10.1016/j.ijpharm.2005.05.017 1:CAS:528:DC%2BD2MXptVWhtr0%3D (Pubitemid 41206604)
15. KA Khan 1975 The concept of dissolution efficiency J Pharm Pharmacol 27 1 48 9 235616 10.1111/j.2042-7158.1975.tb09378.x 1:CAS:528:DyaE2MXhsVCru7o%3D
16. S Furlanetto M Cirri F Maestrelli G Corti P Mura 2006 Study of formulation variables influencing the drug release rate from matrix tablets by experimental design Eur J Pharm Biopharm 62 77 84 16154333 10.1016/j.ejpb.2005. 07.001 1:CAS:528:DC%2BD2MXht1Ontb%2FJ (Pubitemid 41736028)
17. S Janssens JV Humbeeck G Van den Mooter 2008 Evaluation of the formulation of solid dispersions by co-spray drying itraconazole with Inutec SP1, a polymeric surfactant, in combination with PVPVA 64 Eur J Pharm Biopharm 70 2 500 5 18582567 10.1016/j.ejpb.2008.05.025 1:CAS:528:DC%2BD1cXhtFOmtbbM
18. S Chutimaworapan GC Ritthidej E Yonemochi T Oguchi K Yamamoto 2000 Effect of water-soluble carriers on dissolution characteristics of nifedipine solid dispersions Drug Dev Ind Pharm 26 11 1141 50 11068687 10.1081/DDC-100100985 1:CAS:528:DC%2BD3cXnvVSntbY%3D
19. J Chen L Qiu M Hu Y Jin J Han 2008 Preparation, characterization and in vitro evaluation of solid dispersions containing docetaxel Drug Dev Ind Pharm 34 6 588 94 18568908 10.1080/03639040701831835 1:CAS:528:DC%2BD1cXnsVSqsLw%3D (Pubitemid 351878675)
20. G Van den Mooter I Weuts T De Ridder N Blaton 2006 Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs Int J Pharm 316 1-2 1 6 16563676 10.1016/j.ijpharm.2006.02.025 (Pubitemid 43765697)
21. AN Ghebremeskel C Vemavarapu M Lodaya 2007 Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: selection of polymer-surfactant combinations using solubility parameters and testing the processability Int J Pharm 328 2 119 29 16968659 10.1016/j.ijpharm.2006.08.010 1:CAS:528:DC%2BD28XhtlWqurnF (Pubitemid 44895482)
22. T Matsumoto G Zografi 1999 Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization Pharm Res 16 11 1722 8 10571278 10.1023/A:1018906132279 1:CAS:528:DyaK1MXnt1GgsL4%3D (Pubitemid 29530405)
23. AP Simonelli SC Mehta WI Higuchi 1976 Dissolution rates of high energy sulfathiazole-povidone coprecipitates II: characterization of form of drug controlling its dissolution rate via solubility studies J Pharm Sci 65 3 355 61 1263082 10.1002/jps.2600650310 1:CAS:528:DyaE28XhvVCrsLY%3D
24. H Suzuki H Sunada 1998 Influence of water-soluble polymers on the dissolution of nifedipine solid dispersions with combined carriers Chem Pharm Bull (Tokyo) 46 3 482 7 1:CAS:528:DyaK1cXit1Kms7k%3D (Pubitemid 28188567)
25. SL Raghavan A Trividic AF Davis J Hadgraft 2001 Crystallization of hydrocortisone acetate: influence of polymers Int J Pharm 212 2 213 21 11165079 10.1016/S0378-5173(00)00610-4 1:CAS:528:DC%2BD3MXmvFKktw%3D%3D (Pubitemid 32119447)
26. F Usui K Maeda A Kusai K Nishimura K Yamamoto 1997 Inhibitory effects of water-soluble polymers on precipitation of RS-8359 Int J Pharm 154 59 66 10.1016/S0378-5173(97)00129-4 1:CAS:528:DyaK2sXltl2lur0%3D (Pubitemid 27326820)
27. GM Khan Z Jiabi 1998 Formulation and in vitro evaluation of ibuprofen-Carbopol 974P-NF controlled release matrix tablets III: influence of co-excipients on release rate of the drug J Control Release 54 2 185 90 9724905 10.1016/S0168-3659(97)00225-3 1:CAS:528:DyaK1cXksVWntrc%3D (Pubitemid 28342697)
28. Rodriguez CF, Bruneau N, Barra J, Alfonso D, Doelker E. Hydrophilic cellulose derivatives as drug delivery carriers: influence of the substitution type on the properties of compressed matrix tablets. In: Wise DL, editor. Handbook of pharmaceutical controlled release technology. New York, USA: Marcell Dekker; 2000. p. 1-30.
29. L Maggi R Bruni U Conte 2000 High molecular weight polyethylene oxides (PEOs) as an alternative to HPMC in controlled release dosage forms Int J Pharm 195 1-2 229 38 10675700 10.1016/S0378-5173(99)00402-0 1:CAS:528: DC%2BD3cXhtV2ht7w%3D (Pubitemid 30089507)
30. T Ozeki H Yuasa Y Kanaya 2000 Controlled release from solid dispersion composed of poly(ethylene oxide)-carbopol interpolymer complex with various cross-linking degrees of carbopol J Control Release 63 3 287 95 10601724 10.1016/S0168-3659(99)00202-3 1:CAS:528:DyaK1MXnvFSmu7s%3D
31. AA Aboelwafa EB Basalious 2010 Optimization and in vivo pharmacokinetic study of a novel controlled release venlafaxine hydrochloride three-layer tablet AAPS Pharm Sci Tech 11 3 1026 37 10.1208/s12249-010-9467-z 1:CAS:528: DC%2BC3cXhsFemsb7E